Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

18 trials with published results (20%)

Research Maturity

51 completed trials (57% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

6.7%

6 terminated out of 89 trials

Success Rate

89.5%

+3.0% vs benchmark

Late-Stage Pipeline

39%

35 trials in Phase 3/4

Results Transparency

35%

18 of 51 completed with results

Key Signals

18 with results89% success

Data Visualizations

Phase Distribution

76Total
Not Applicable (25)
P 1 (1)
P 2 (15)
P 3 (12)
P 4 (23)

Trial Status

Completed51
Unknown13
Recruiting9
Terminated6
Withdrawn5
Not Yet Recruiting4

Trial Success Rate

89.5%

Benchmark: 86.5%

Based on 51 completed trials

Clinical Trials (89)

Showing 20 of 20 trials
NCT07568093Not ApplicableRecruitingPrimary

PARO-agitation-study

NCT06718764Not ApplicableRecruiting

Neurosteer Bedside Monitoring System

NCT05644262Phase 2Active Not RecruitingPrimary

Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

NCT07552896Not Yet RecruitingPrimary

Effect of Daily Screen Time on Postoperative Emergence Delirium in Children Aged 2-11 Years

NCT06937229Phase 3Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06052254Phase 2RecruitingPrimary

Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type

NCT07377981Phase 4Not Yet Recruiting

An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium: Protocol of a Randomized Controlled Trial

NCT06808984Phase 2RecruitingPrimary

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

NCT04516057Phase 3Recruiting

Nabilone for Agitation Blinded Intervention Trial

NCT05974527Phase 4WithdrawnPrimary

Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department

NCT05397639Phase 3RecruitingPrimary

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

NCT05271552Phase 3CompletedPrimary

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

NCT05557409Phase 3Completed

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT05522647Recruiting

Detection of Risk Behaviors: Pilot Observational Study With Bedridden and Agitated Patients.

NCT06578819Not ApplicableCompleted

Doll Therapy for Agitated Elderly Dementia People

NCT07051096Not ApplicableNot Yet Recruiting

Responsive Nature-Driven Imagery to Reduce Delirium After Cardiac Surgery

NCT06993194Not ApplicableNot Yet Recruiting

Comparison of Haloperidol and Dexmedetomidine for Delirium and Agitation in ICU Patients With Traumatic Brain Injury

NCT06752616Phase 2RecruitingPrimary

Acute Agitation in Emergency Psychiatry

NCT02129348Phase 2Completed

Treatment of Psychosis and Agitation in Alzheimer's Disease

NCT05665088Phase 3TerminatedPrimary

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Scroll to load more

Research Network

Activity Timeline